Predictors of Loss to Follow-Up among HIV-Infected Adults after Initiation of the First-Line Antiretroviral Therapy at Arba Minch General Hospital, Southern Ethiopia: A 5-Year Retrospective Cohort Study

Table 2

Baseline clinical-, immunological-, and treatment-related characteristics of HIV-positive adults on ART in Arba Minch General Hospital, Southern Ethiopia, 2019 ().

Characteristics	Categories	Frequency ()	Percentage (%)
Initial regimen		498	98.0
		3	0.6
		4	0.8
		3	0.6
ART pills per a day	One	491	96.7
	Two	17	3.4
CPT at start of ART	Yes	284	55.9
	No	224	44.1
Comedication other than CPT	Yes	111	21.9
	No	397	78.2
TB at start	Yes	84	16.5
	No	424	83.5
OIs other than TB at the start	Yes	85	16.7
	No	423	83.3
Comorbidity other than OIs	Yes	11	2.2
	No	497	97.8
Functional status	Working	395	77.8
	Ambulatory and bedridden	113	22.2
WHO clinical stage	Stage I	271	53.4
	Stage II	97	19.1
	Stage III	124	24.4
	Stage IV	16	3.2
Baseline weight (in kg)	≤60 kg	384	75.6
	>60 kg	124	24.4
Baseline CD4 count (cells/mm^3)	<100 cells/mm^3	88	17.3
	100–199 cells/mm^3	89	17.5
	200–349 cells/mm^3	155	30.5
	≥350 cells/mm^3	176	34.7
Baseline HGB (g/dL)	<7 g/dL	10	2.4
	7–9.9 g/dL	60	11.8
	10–12.9 g/dL	306	60.2
	≥13 g/dL	132	25.9
Baseline creatinine	0.00–0.59 mg/dL	93	18.3
	0.6–1.2 mg/dL	379	74.6
	>1.2 mg/dL	36	7.1
Baseline alanine transaminase (IU/L)	<7 IU/L	9	1.8
	7–56 IU/L	472	92.9
	>56 IU/L	27	5.31
Drug side effect	Yes	157	30.9
	No	351	69.1
Treatment duration	<1 year	198	38.9
	1–2 years	109	21.5
	>2 years	201	39.6

ART: antiretroviral therapy; AZT: zidovudine; CD4: clusters of differentiation; CPT: cotrimoxazole prophylaxis therapy; EFV: efavirenz; HGB: hemoglobin; IU/L: international unit per liters; kg: kilogram; TDF: tenofovir; +3TC: lamivudine; NVP: nevirapine; TB: tuberculosis; OIs: opportunistic infections; WHO: World Health Organization.